Get the app
US › Healthcare

Fortrea Holdings Inc. (FTRE)

US · Healthcare · Biotechnology

$21.96+7.33%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue
$691.5M
Revenue YoY
-1.4%
Net profit
$600,000
EPS
$0.28
EPS estimate
$0.24
Net margin
0.1%

EPS came in at 0.28 against a street estimate of 0.24 — a beat of 16.7%.

Key statistics

Market cap
$2.05B
Forward P/E
10.9
P/B
3.86
Book value
$5.52
EPS (TTM)
$-0.73
52-week high
$26.16
52-week low
$8.55
50-day MA
$20.28
200-day MA
$15.70
Beta
1.91

Analyst view

Analysts rate Fortrea Holdings Inc. a buy (7 buy, 4 hold, 2 sell out of 13) with an average price target of $22.62.

From the latest earnings call · 2026-10-29

CONFIDENT Fortrea delivered improving profitability, bookings above revenue and stronger cash flow, raised 2026 guidance, and expanded early-phase capacity through an acquisition. Q3 FY26 Management highlighted China as a source of global drug-development opportunity and expanded U.S./U.K. early-phase capacity through the acquisition. Analysts focused on fourth-quarter profitability, the backlog reset, demand by customer and segment, acquisition economics, and 2027 prospects. Management emphasized fewer working days, inactive or non-deliverable contract scope, broadening demand, and gradual commercial conversion. 2026-10-29…

Full summary in the app.

Shareholding

Insiders
1.21%
Institutions
106.87%

Largest institutional holders

FundStake
BlackRock Inc16.61%
The Goldman Sachs Group Inc8.85%
Sessa Capital, L.P4.83%
Vanguard Capital Management, LLC4.40%
Vanguard Portfolio Management, LLC4.01%
State Street Corp3.98%
FMR Inc3.83%
Corvex Management LP3.14%

Recent filings & reports

DocumentDate
Quarterly report · Q3 2026
HEADLINE NUMBERS • Third-quarter 2026 revenue was $691.5 million, down from $701.3 million in Q3 2025. • Nine-month 2026 revenue was $2,006.2 millio
2026-10-29
Results announced · Q4 2026
HEADLINE NUMBERS • Q3 2026 revenue was $691.5 million, down from $701.3 million in Q3 2025. • GAAP net income was $0.6 million, or $0.01 per diluted
2026-10-29
Board / officer change · Q3 2026
OTHER NOTABLE POINTS • Fortrea Holdings Inc. appointed Carrie Russell as Chief Accounting Officer, effective October 5, 2026. • Russell has served a
2026-09-30
Board / officer change · Q3 2026
FORTREA HOLDINGS INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Fortrea Holdings Inc. is a publicly traded company on NASDAQ under ticker s
2026-09-10
Quarterly report · Q2 2026
FORTREA HOLDINGS INC. — 10-Q SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Revenues (6 months ended June 30, 2026): $1,314.7 million vs. $1,3
2026-07-29
Results announced · Q3 2026
FORTREA – Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $678.2 million (down from $710.3 million in Q2 2025) • H1 2026 Revenue: $1,314
2026-07-29
Board / officer change · Q3 2026
FORTREA HOLDINGS INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Chief Accounting Officer Robert A. Parks resigning effective August 7, 2026 • Chief Fina
2026-07-14
Board / officer change · Q2 2026
FORTREA HOLDINGS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • New CFO appointment effective July 6, 2026 (Jason Knoblauch replacing Jill McConnell) •
2026-06-26

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fortrea Holdings Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-11-07.